Skip to main content
. 2022 Oct 16;29(10):7816–7831. doi: 10.3390/curroncol29100618

Table 4.

Published details of other rare ALK fusions positive NSCLC patients treated with ALK-TKIs.

Ref Rare ALK
Fusion Types		 Merge Mutations ALK-TKIs Treatment Response
1 Cao Q, et al. [96] NCOA1–ALK CDAK27Q, ERCC1N118N, DPYDI543V, MTHFRA222V,GSTP1I105V Crizotinib Third line PFS > 18 m
2 Fang, W. et al. [97] MPIP-ALK Crizotinib Second line PFS > 11 m
3 Tian, P. et al. [89] CHRNA7-ALK Crizotinib First line PFS: 18 m
4 Tian, P. et al. [89] LOC349160-ALK Crizotinib First line PFS: 7 m
5 Tian, P. et al. [89] TACR1-ALK Crizotinib First line PFS: 15 m
6 Tian, P. et al. [89] CENPA-ALK Crizotinib First line PFS: 4 m
7 Tian, P. et al. [89] DYSF-ALK
ITGAV-ALK		 ALK p.Q1146P;
MET p.M636V		 Crizotinib First line PFS: 23 m
8 Chen, H.F. et al. [101] SOS1-ALK Crizotinib First line PFS > 6 m
9 Li, M. et al. [71] LMO7-ALK NRG1 c.602A > T;TP53 Alectinib
Ensartinib		 First line
Second line		 PD
PFS > 18 m